14 completed, 6 active not recruiting, 5 terminated, 4 recruiting. 36 Phase 3, 12 Phase 2.
Follow Osteochondrodysplasias: new trials by email Literature Review of Osteochondrodysplasias trials Research Report on Osteochondrodysplasias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia Dual therapy with navepegritide and lonapegsomatropin, Dual therapy with navepegritide and placebo for lonapegsomatropin, Dual therapy with lonapegsomatropin and placebo for navepegritide - Achondroplasia | Phase 3 | Not yet recruiting | Ascendis Pharma A/S | 144 | 2026-11-01 | 2026-11-12 |
| Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia BMN 333, Vosoritide Injection [Voxzogo] - Achondroplasia | Phase 2 / Phase 3 | Recruiting | BioMarin Pharmaceutical | 160 | 2026-04-20 | 2026-10-22 |
| Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta Vitamin D, Calcium - Osteogenesis Imperfecta | Phase 3 | Recruiting | Amgen | 71 | 2026-03-18 | 2026-11-17 |
| An Interventional Study of Infigratinib in Children With Hypochondroplasia infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day - Hypochondroplasia | Phase 2 / Phase 3 | Enrolling by invitation | QED Therapeutics, a BridgeBio company | 24 | 2025-04-22 | 2026-07-16 |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | Bicara Therapeutics | 650 | 2025-01-28 | 2026-10-29 |
| Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia(AOBA Study) KK8398 - Achondroplasia | Phase 3 | Active not recruiting | Kyowa Kirin Co., Ltd. | 13 | 2024-12-01 | 2026-10-08 |
| Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta setrusumab - Osteogenesis Imperfecta | Phase 3 | Active not recruiting | Ultragenyx Pharmaceutical Inc | 6 | 2024-10-25 | 2026-09-28 |
| Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome Etanercept, Placebo - SAPHO Syndrome | Phase 2 / Phase 3 | Recruiting | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | 60 | 2024-09-04 | 2026-04-13 |
| Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia Vosoritide, Placebo - Hypochondroplasia | Phase 3 | Completed | BioMarin Pharmaceutical | 81 | 2024-06-17 | 2026-11-12 |
| Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta Romosozumab, Bisphosphonate - Osteogenesis Imperfecta | Phase 3 | Active not recruiting | Amgen | 111 | 2024-04-22 | 2026-05-27 |
| A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day - Achondroplasia | Phase 3 | Completed | QED Therapeutics, a BridgeBio company | 114 | 2023-11-10 | 2026-03-17 |
| A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia TransCon CNP - Achondroplasia | Phase 2 / Phase 3 | Enrolling by invitation | Ascendis Pharma Growth Disorders A/S | 140 | 2023-06-21 | 2026-08-17 |
| Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Bisphosphonate, Setrusumab - Osteogenesis Imperfecta | Phase 3 | Active not recruiting | Ultragenyx Pharmaceutical Inc | 69 | 2023-06-14 | 2026-10-20 |
| A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia Navepegritide (TransCon CNP), Placebo for Navepegritide (TransCon CNP) - Achondroplasia | Phase 2 / Phase 3 | Completed | Ascendis Pharma Growth Disorders A/S | 84 | 2023-03-03 | 2026-07-14 |
| Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis Pioglitazone 30mg, Empagliflozin 10 MG - Non Alcoholic Steatohepatitis | Phase 3 | Unknown | Tanta University | 56 | 2022-11-01 | 2022-11-04 |
| Setrusumab vs Placebo for Osteogenesis Imperfecta Setrusumab, Placebo - Osteogenesis Imperfecta | Phase 2 / Phase 3 | Active not recruiting | Ultragenyx Pharmaceutical Inc | 183 | 2022-02-21 | 2026-10-20 |
| Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC M7824, Placebo, Gemcitabine - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 / Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 309 | 2019-09-20 | 2023-11-14 |
| Effects of Soy Isoflavone on Bone Health Among Saudi Female Students Imam Abdulrahman Bin Faisal University. Soy Isoflavone supplement - Soy Isoflavone Effect, Bone Density, Low | Phase 3 | Completed | Imam Abdulrahman Bin Faisal University | 28 | 2018-12-12 | 2023-09-28 |
| Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta Denosumab, Alternative osteoporosis medications - Osteogenesis Imperfecta (OI) | Phase 3 | Terminated | Amgen | 75 | 2018-07-26 | 2022-12-20 |
| An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia BMN 111 - Achondroplasia | Phase 3 | Active not recruiting | BioMarin Pharmaceutical | 119 | 2017-12-12 | 2026-03-13 |
Showing 20 of 36. Sign in to see all of them.
Osteogenesis Imperfecta (11) · Achondroplasia (8) · Genetic Diseases, Inborn (7) · Bone Diseases (6) · Dwarfism (6) · Musculoskeletal Diseases (6) · Camurati-Engelmann Syndrome (5) · Osteopetrosis (4) · Bone Diseases, Developmental (3) · Collagen Diseases (2) · Hip Dislocation, Congenital (2) · Hypochondroplasia (2) · Mucopolysaccharidosis IV (2) · Osteoarthritis (2)
Bone Diseases, Developmental (33) · Bone Diseases (30) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (30) · Musculoskeletal Diseases (30) · Genetic Diseases, Inborn (21) · Skin and Connective Tissue Diseases (17) · Connective Tissue Diseases (16) · Collagen Diseases (11) · Endocrine System Diseases (7) · Dwarfism (4) · Metabolic Diseases (4) · Neoplasms (4) · Nutritional and Metabolic Diseases (4) · Osteosclerosis (4)
vosoritide (4) · Busulfan (3) · Cyclophosphamide (3) · setrusumab (3) · Alemtuzumab (2) · Denosumab (2) · Diphosphonates (2) · Risedronic Acid (2) · fludarabine (2) · fludarabine phosphate (2) · infigratinib (2) · thymoglobulin (2) · Anastrozole (1) · Antilymphocyte Serum (1) · Calcitriol (1)
Amgen (4) · BioMarin Pharmaceutical (4) · Ultragenyx Pharmaceutical Inc (3) · Ascendis Pharma Growth Disorders A/S (2) · DePuy International (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · QED Therapeutics, a BridgeBio company (2) · Ascendis Pharma A/S (1) · Bicara Therapeutics (1) · Columbia University (1) · EMD Serono Research & Development Institute, Inc. (1) · FDA Office of Orphan Products Development (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Fudan University (1) · Imam Abdulrahman Bin Faisal University (1)
United States (22) · Australia (15) · United Kingdom (15) · Germany (14) · Canada (13) · Italy (13) · Spain (13) · France (12) · Japan (10) · Poland (10) · Belgium (7) · Hungary (5) · Turkey (Türkiye) (5) · Austria (4) · China (4)
Joan C Marini, M.D. (2) · Amir Ali Hamidieh, MD (1) · Dietrich H Wenderoth, MD (1) · Eloisa Arbustini, MD,FESC,FACC (1) · Francis H. Glorieux, MD, PhD (1) · James Garvin, MD, PhD (1) · Jiayi Chen, MD (1) · L. Lyndon Key, Jr. (1) · Luigi Tavazzi, MD,FESC,FACC (1)
PMID 42470570, PMID 38649657, PMID 39305160, PMID 39740666, PMID 16601194, PMID 17188619, PMID 17911499, PMID 19430350, PMID 23927913, PMID 24474088, PMID 32461347, PMID 34431071, PMID 38875119, PMID 41247754, PMID 42144862, PMID 42370681, PMID 42713641
2023 (3), 2014 (1), 2015 (1), 2017 (1), 2018 (1), 2019 (1)